This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/drug/DB06590/identifier/kegg-drug/
n20http://www.pdr.net/MedMerck-full-prescribing-information/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06590/identifier/drugbank/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n18http://www.drugs.com/
n21http://www.rxlist.com/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06590/identifier/national-drug-code-directory/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://linked.opendata.cz/resource/drugbank/patent/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06590/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06590/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06590
rdf:type
n3:Drug
n3:description
Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections. Community-acquired bacterial pneumonia.
n3:dosage
n19:271B4CF1-363D-11E5-9242-09173F13E4C5 n19:271B4CF2-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Steed ME, Rybak MJ: Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy. 2010 Apr;30(4):375-89. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20334458 # Kollef MH: New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009 Dec;11(4):282-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/ 20001879 # Kanafani ZA, Corey GR: Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol. 2009 Feb;4(1):25-33. doi: 10.2217/17460913.4.1.25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19207097 # Parish D, Scheinfeld N: Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs. 2008 Feb;9(2):201-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18246523 # Macgowan AP, Noel AR, Tomaselli S, Bowker KE: Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2013 Mar 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23459495
n3:group
approved investigational
n3:halfLife
1.60 hours (600 mg dose).
n3:indication
Ceftaroline fosamil is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms.
owl:sameAs
n7:DB06590
dcterms:title
Ceftaroline fosamil
adms:identifier
n9:Ceftaroline_fosamil n10:D08884 n11:0456-0600-01 n12:70718 n13:DB06590
n3:mechanismOfAction
Ceftaroline fosamil is an antibacterial drug.
n3:patent
n4:6417175
n3:routeOfElimination
primarily eliminated by the kidneys (6% in feces within 48 hours).
n3:synonym
(6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Ceftaroline Teflaro PPI 0903
n3:toxicity
LD50/LC50: Draize test, rabbit, eye: 100 mg/24H Moderate; Oral, mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat: LD50 = 980 mg/kg.
n3:volumeOfDistribution
Median 20.3 L (18.3-21.6 L).
n3:proteinBinding
approximately 20%.
n3:synthesisReference
http://www.google.com/patents/US20110071114
foaf:page
n18:teflaro.html n20:teflaro?druglabelid=158 n21:teflaro-drug.htm
n3:IUPAC-Name
n5:271B4CF7-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4CFD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4CFC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4CF9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4CFA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4CFB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4CF5-363D-11E5-9242-09173F13E4C5 n5:271B4D0D-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4CF3-363D-11E5-9242-09173F13E4C5 n5:271B4CF6-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4CF4-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:J01DI02
n3:H-Bond-Acceptor-Count
n5:271B4D03-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4D04-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4CFE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4CFF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4D01-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4D00-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4D02-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Streptococcus pneumoniae Gram-negative Bacteria Staphylococcus aureus Gram-positive Bacteria
n3:casRegistryNumber
400827-46-5
n3:category
n3:Bioavailability
n5:271B4D09-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4D0B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4D0C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4D08-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4D07-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4D0A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4CF8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4D05-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4D06-363D-11E5-9242-09173F13E4C5